If this message displays incorrectly, please view the web page

MAY 29, 2015

Research Extras

 
CHAMPS is a global disease surveillance network based first at six sites, but expandable over 20 years to 20 sites. The network could be repurposed for an emerging epidemic.

GLOBAL HEALTH
Gates Foundation names Emory Global Health Institute as lead partner in network to track and reduce childhood mortality
Emory was selected by the Bill & Melinda Gates Foundation to lead a new global child health surveillance network centered in sub-Saharan African and South Asia. The network, CHAMPS, will gather data about how, where and why seven million children are getting sick and dying from preventable causes each year. The Gates Foundation plans an initial $75 million commitment to the network that will partner with governments and national public health institutes to better diagnose, characterize, manage, treat and prevent specific causes of disease. Read more...


 
 
Bone marrow cells harvested from children and adults will be used to manufacture large numbers of personalized cells.
HEMATOLOGY/ONCOLOGY/TRANSPLANTATION
Clinical trial uses patients' cells to fight complications of bone marrow transplant
A clinical trial using personalized cell therapy is designed to help reduce graft-versus-host disease, a life-threatening complication of bone marrow transplantation (BMT) in which donor immune lymphocytes attack the organs of the transplant recipient. BMT is used to treat some patients with leukemia and other blood and bone marrow disorders. Read more...



Reducing measles infection appears to cause a drop in deaths from other infectious diseases.
INFECTIOUS DISEASES
Measles causes long-lasting effects of "immune amnesia"
The measles virus can suppress the immune systems of children for up to three years, wiping out already existing immunity and leaving children highly susceptible to a host of other diseases. Researchers say their findings show the measles vaccine has benefits that extend beyond protection against the measles virus itself. Read more...



A new anti-cancer compound is being studied in lung cancer but could be applied to other cancers as well.
CANCER
New Molecular Approach Promotes Death of Lung Cancer Cells
A new compound helps promote the death of cancer cells in the laboratory by inhibiting a protein called Bcl-2. The potential drug could provide a new weapon against lung cancer by converting Bcl-2 from its normal role in protecting cancer cells to one of promoting apoptosis, or death of cancer cells. Researchers soon hope to test the drug in eligible patients. Read more...



Editor, Holly Korschun, Executive Director of Research Communications
Managing Editor, David S. Stephens, MD, Vice President for Research